Drugs / CU-40101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05380427 | Aug 2022 → Nov 2023 | androgenetic alopecia | Cutia Therapeutics (Wuxi) Co., Ltd | Completed | Met primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-11-02 | Cutia Therapeutics（Wuxi）Co.,Ltd | Results VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL OF CU-40101 (TOPICAL SMALL MOLECULE THYROID HORMONE RECEPTOR AGONIST LINIMENT) IN CHINA REACHED PRIMARY ENDPOINT cutiatx.com ↗
The board of directors (the “Board”) of the Company is pleased to announce that the Phase I clinical trial of the Group ’s CU-40101 (topical small molecule thyroid hormone receptor agonist liniment) conducted in China for the treatment of androgenetic alopecia reached primary endpoint. |
| 2023-11-02 | Cutia Therapeutics（Wuxi）Co.,Ltd | Results 自願公告 - CU-40101（外用小分子甲狀腺激素受體激動劑搽劑）中國I期臨床試驗達到主要終點 cutiatx.com ↗ |
All press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-11-02 | Cutia Therapeutics（Wuxi）Co.,Ltd | VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL OF CU-40101 (TOPICAL SMALL MOLECULE THYROID HORMONE RECEPTOR AGONIST LINIMENT) IN CHINA REACHED PRIMARY ENDPOINT cutiatx.com ↗ |
| 2023-11-02 | Cutia Therapeutics（Wuxi）Co.,Ltd | 自願公告 - CU-40101（外用小分子甲狀腺激素受體激動劑搽劑）中國I期臨床試驗達到主要終點 cutiatx.com ↗ |
| 2023-08-28 | Cutia Therapeutics（Wuxi）Co.,Ltd | VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL OF CU-40101 (TOPICAL SMALL MOLECULE THYROID HORMONE RECEPTOR AGONIST LINIMENT) COMPLETED DATABASE LOCK cutiatx.com ↗ |
| 2023-08-28 | Cutia Therapeutics（Wuxi）Co.,Ltd | 自愿公告 - CU-40101（外用小分子甲状腺激素受体激动剂搽剂）I期临床试验完成数据库锁定 cutiatx.com ↗ |
| 2023-07-17 | Cutia Therapeutics（Wuxi）Co.,Ltd | VOLUNTARY ANNOUNCEMENT - ALL ENROLLED PATIENTS COMPLETED PHASE I CLINICAL TRIAL OF CU-40101 (TOPICAL SMALL MOLECULE THYROID HORMONE RECEPTOR AGONIST LINIMENT) cutiatx.com ↗ |
| 2023-07-17 | Cutia Therapeutics（Wuxi）Co.,Ltd | 自愿公告 - CU-40101（外用小分子甲状腺激素受体激动剂搽剂）I期临床试验完成所有受试者出组 cutiatx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CU-40101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05380427 ↗ |
| Route | Topical | “multiple topical skin application” NCT05380427 ↗ |